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1. InTroDuCTIon
The lipid profile, which is routinely done to as-
sess a cardiovascular risk, involves the measure-
ment/calculation of serum/plasma levels of total 
cholesterol (TC), high-density lipoprotein choles-
terol (HDL-C), low-density lipoprotein cholesterol 
(LDL-C), triglycerides (TG) and non-HDL cholester-
ol (non-HDL-C), although LDL-C measurement still 
plays a  key role in the diagnosis, prediction and 
the monitoring of both the course and treatment 
of lipid disorders [1–3]. The results of the meas-
urements indirectly and approximately reflect the 
blood content of individual lipoproteins. Quanti-
tative measurement of atherogenic lipoproteins, 
i.e. LDL, lipoprotein(a) [Lp(a)], chylomicron (CM) 
remnants and very low-density lipoprotein (VLDL) 
remnants, is of special importance in laboratory 
assessment of lipid metabolism and the risk of 
atherosclerosis progression [2, 3]. This is why lipid 
profile, which usually applies only to the LDL level, 
should be supplemented with the measurement 
of Lp(a) as well as CM and VLDL remnants, if pos-
sible.
Lipoproteins are a family of large particles com-
posed of an “envelope”, which contains phospho-
lipids and free cholesterol, and a core containing 
TG and cholesterol esters. The lipid part is bound 
to specific proteins – apolipoproteins (apo), which 
determine the physical and biological properties 
of lipoproteins [3]. Lipids are not covalently at-
tached to proteins. The structure of lipoproteins is 
maintained primarily by hydrophobic interactions 
between nonpolar components of lipids and pro-
teins. Lipoprotein classification reflects the parti-
cle size and density in the aqueous plasma envi-
ronment as well as the content of apolipoproteins 
(Figure 1). Triglyceride-rich CM and VLDL as well 
as CM and VLDL remnants have a density of less 
than 1.006 g/ml. LDL, HDL and Lp(a) are lipopro-
teins with a density of over 1.006 g/ml [3].
The system of lipid transport with the involve-
ment of lipoproteins has two main functions: 
•	 Transport of triglycerides from the intestine 
and liver to the adipose tissue and muscles (in-
testinal pathway);
•	 Supply of cholesterol to the peripheral tissues, 
where it is essential for the formation of cell 
membranes and biosynthesis of steroid hor-
mones, and to the liver, where it is used for the 
synthesis of bile acids (hepatic pathway) (Fig-
ure 2).
Dietary TG are hydrolysed in the intestine 
into free fatty acids (FFA), mono- and diglycer-
ides, absorbed with the exogenous cholesterol 
by enterocytes, in which CM that transport them 
are formed and subsequently enter the circula-
tion through the lymphatic system. Lipoprotein 
lipase (LPL) bound to the capillary endothelium 
of the adipose tissue and muscles hydrolyses 
the TG they contain into glycerol and FFA, form-
ing CM remnants contained in the intermediate 
density lipoproteins (IDL) fraction [1–3]. Endog-
enous TG are synthesized in hepatocytes, where 
figure 1. Plasma lipoprotein particles size and density with the cholesterol they contain as a marker of their plasma 
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jointly with cholesterol and apolipoproteins 
(apoB 100, apoE, apoC) constitute building ma-
terial for VLDL secreted into the blood, where 
their remnants (IDL) are formed by an action of 
endothelial lipase (EL). LDL are formed from IDL 
with the involvement of hepatic lipase (HL) and 
are enriched with HDL cholesterol, with the in-
volvement of the cholesterol ester transfer pro-
tein (CETP) [1–3].
HDL particles are formed in the liver and in-
testine as well as in the course of CM and VLDL 
degradation, from their superficial phospholipids 
and free cholesterol. The free cholesterol is taken 
up from peripheral cells (including macrophages 
in the vascular wall) by nascent HDL and HDL3 
subfraction, with the involvement of ATP-binding 
cassette transporter A1 (ABC1), which binds to 
apoA-I  and is subsequently esterified by plasma 
lecithin–cholesterol acyltransferase (LCAT) [1–3]. 
Cholesterol esters are transported by mature 
HDL2 bound by the scavenger receptor, class B 
type 1 (SR-B1) in hepatocytes, where they are 
used for bile acid synthesis. This is a so-called di-
rect mechanism of reverse cholesterol transport. 
By an indirect mechanism, CETP transfers them 
from HDL to apoB-containing lipoproteins, with an 
exchange for TG. ApoB-containing lipoproteins are 
uptaken by the liver via LDL receptors as well as 
other membrane receptors (VLDL receptors, apoE 
receptors). TG hydrolysis in HDL2 by HL leads to 
the formation of HDL3 (Figure 2) [2–4]. 
Currently available analytical methods pro-
vide only indirect, approximate insight into the 
transformation of both cholesterol and TG or the 
metabolism and functions of lipoproteins. In clin-
ical practice, the diagnostics of lipid metabolism 
disorders is a part of the assessment and control 
of the risk for atherosclerosis and related cardi-
ovascular diseases (CVD). Therefore, laboratory 
work-up for dyslipidemia, defined as a condition 
in which blood levels of lipids and lipoproteins are 
outside the desirable range, is aimed at measur-
ing the amount of atherogenic lipoproteins in the 
blood. The methodological approach to lipopro-
teins measurement is diversified – its blood con-
tent may be determined directly as the number of 
particles (LDL-P, HDL-P, Lp(a)-P) or their concentra-
tion, or indirectly by measuring the concentration 
their individual components – cholesterol or apoli-
poprotein (apoB, apoA-I).
2. orGAnISATIon of THe GuIDeLIneS 
The members of the Steering Committee who 
prepared these guidelines were selected by the 
Polish Society of Laboratory Diagnostics (PSLD) 
figure 2. Lipoprotein metabolism and transport
ABCA1 – ATP-binding cassette transporter A1, CETP – cholesterol ester transfer protein, EL – endothelial lipase, HL – hepatic 
lipase, LCAT – lecithin cholesterol acyltransferase, LPL – lipoprotein lipase, PLTP – phospholipid transfer protein, TG – triglycerides.
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and the Polish Lipid Association (PoLA) as experts 
in the diagnosis and treatment of lipid metabolism 
disorders. The Steering Committee has carried 
out a  detailed review of the published scientific 
evidence on the management of dyslipidemia, in-
cluding its diagnosis, treatment, monitoring and 
prevention, as well as critical evaluation of the 
diagnostic and therapeutic procedures, includ-
ing the benefit-risk assessment. Every chapter is 
summarized in a box containing clear and easy to 
understand recommendations, highlighting the 
information that needs to be remembered and the 
key points of the recommendation. 
The experts comprising the teams that devel-
oped and peer-reviewed the guidelines filled in 
the conflict of interest forms with regard to all re-
lationships which might be perceived as actual or 
potential sources of conflicts of interest. After the 
final approval of the guidelines, the final version 
of the document is published simultaneously in 
the Diagnostyka Laboratoryjna (Journal of Labora-
tory Diagnostics), indicated by PSLD and Archives 
of Medical Science (indicated by PLA).
Laboratory diagnosticians and physicians of 
various specialties who deal with patients with 
lipid disorders are encouraged to take fully into 
account these guidelines when conducting clin-
ical assessments as well as defining and imple-
menting medical prevention, diagnosis or treat-
ment strategies. Nonetheless, the guidelines 
in no way absolve physicians from individual 
responsibility for making right and accurate de-
cisions, taking into account the patient’s health 
status and in consultation with the patient and, 
if necessary, with his/her caregiver. Healthcare 
professionals are responsible for verification of 
policies and regulations with regard to medi-
cines and equipment at the time they are pre-
scribed/used.
3. PreAnALyTICAL ConSIDerATIonS
Tests comprising lipid profile, standard ones 
(TC, HDL-C, LDL-C, TG) as well as additional mea-
surements of apoB and Lp(a), are performed in 
serum or plasma. The general approach to the 
pre-analytical phase is based on the assumption 
that lipid profile should be assessed in the set-
ting of everyday activity and diet, and people are 
not in the fasted state for about 16 h a day [4, 5]. 
Therefore, blood samples for these tests do not 
need to be collected in the fasting state [6]. This 
approach is also recommended in the 2016 posi-
tion statement of the European Atherosclerosis 
Society (EAS) and the European Federation of Clin-
ical Chemistry and Laboratory Medicine (EFLM), 
which was based on data indicating that a slight 
postprandial increase in the TG level (to 27 mg/dl 
(0.3 mmol/l) does not result in significant changes 
in the lipid profile assessment compared to the 
testing of fasting samples. Small differences in the 
interpretation of results pertain to TG, non-HDL-C 
and the CM and VLDL remnants cholesterol. It is 
recommended that lipid profile be repeated in 
the fasting sample if the non-fasting TG level is 
> 4.5 mmol/l (400 mg/dl) [2, 6].
recommendations
Routine lipid profile testing, primarily LDL-C 
and TC, does not require fasting samples. Re-
testing using material collected in the fasting 
state should be considered if non-fasting TG is 
> 4.5 mmol/l (400 mg/dl).
The levels of individual lipid profile compo-
nents are characterized by intraindividual vari-
ability of 5–10% for TC and > 20% for TG. In ad-
dition to genetically determined mechanisms of 
lipid metabolism regulation, variability in TC levels 
is also caused by environmental factors such as 
physical activity, diet, smoking or long-term alco-
hol abuse while variability in TG levels is affected 
by diet, including carbohydrate and alcohol intake, 
and physical activity. Changes in lipid profile occur 
during pregnancy, especially in the third trimester 
(predominantly an increase in the TG, TC and Lp(a) 
levels, to a lesser degree the LDL-C and HDL-C lev-
els) [7]. Seasonal variation is also observed, with 
increases in TC and TG levels during winter [5, 8, 9]. 
The TC and LDL-C levels are lower for several 
weeks after a CV event and in the course of chron-
ic inflammation, e.g. rheumatic disease (lipid 
paradox), as well as in the elderly, especially over 
75 years old [10–12]. 
Due to the fact that cholesterol and TG are com-
ponents of macromolecular lipoproteins, wearing 
a  constricting band for ≥ 3 min or remaining in 
the standing position for more than 30 min before 
blood sampling may cause a 10–12% increase in 
their levels as a result of the so-called haemocen-
tration effect. Serum levels of TC, HDL-C, LDL-C 
and TG are approximately 3% higher than the 
plasma levels. Serum or plasma samples may be 
stored at a  refrigeration temperature (+4°C) for 
up to 4 days. Longer storage requires freezing at 
–70°C.
4. TrIGLyCerIDeS
Triglycerides, triacylglycerol (TG), glycerol and 
long-chain fatty acids esters comprise the main 
components of the adipose cells and the main 
source of energy for the body. An increased TG lev-
el coexists with a low level of HDL-C and a high lev-
el of small-dense low-density lipoproteins (sdLDL) 
(atherogenic dyslipidemia). From a practical point 
of view, TG determination is critically important in 
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assessing residual risk because a high level, even 
with a targeted LDL-C levels, significantly increas-
es the risk of cardiovascular events [13, 14].
4.1. Methods of determination
TG is determined using enzymatic methods, 
usually after the release of glycerol by enzymat-
ic or alkaline hydrolysis. Typically, TG in a serum/
plasma sample are exposed to LPL, which results 
in the release of glycerol and FFA. Subsequently, 
3-phosphoglycerol and adenosine-5-diphosphate 
(ADP) are formed from glycerol with the involve-
ment of glycerol kinase and ATP. In a successive 
reaction, in the presence glycerol phosphate oxi-
dase from 3-phosphoglycerol and molecular oxy-
gen (O2), dihydroxyacetone phosphate and H2O2 
are formed. H2O2 reacts with 4-chlorophenol and 
4-aminoantipyrine, forming red-coloured qui-
noneimine (Trinder reaction) [15]. The intensity of 
the colour originating from quinoneimine, propor-
tional to TG concentration in the tested material, 
is measured by spectrophotometry in automated 
analysers [16].
The total allowable error for TG concentration 
recommended by the American National Choles-
terol Education Program (NCEP) is ±15%, while 
the one adopted by the Centre for Quality Assess-
ment in Laboratory Medicine in Poland (COBJwDL) 
– ±10%.
4.2. Reporting of results
Alongside the TG level, a  laboratory report 
should include information on the desirable (tar-
get) values with regard to cardiovascular risk as 
well as alarming values indicating severe dyslip-
idemia (Table I).
5. ToTAL CHoLeSTeroL
Cholesterol is one of the best-known lipids, 
which results from, among others, its direct con-
nection with the development of atherosclerosis. 
Cholesterol in the body comes from the diet as 
well as biosynthesis taking place in the majority 
of cells, primarily in hepatocytes and enterocytes. 
Table I. Desirable and alarming TG plasma/serum 
levels [6, 8, 17]
Desirable levels TG level 
[mg/dl]
TG level 
[mmol/l]
Fasting < 150 < 1.7
Non-fasting < 175 < 2.0
Alarming levels
Suspected chylomicronaemia 
syndrome with a high risk of 
acute pancreatitis
> 880 > 10.0
Unit conversion: [mg/dl] × 0.011 = [mmol/l].
In the blood, it is transported primarily in LDL, and 
only about 30% of its circulating pool is found 
in HDL, VLDL, and CM and VLDL remnants. Thus, 
determination of the TC concentration indirectly 
reflects an approximate plasma LDL level. From 
a  clinical point of view, the TC level is currently 
used only in the cardiovascular risk stratification 
SCORE risk chart and to assess the severity of hy-
percholesterolemia if the LDL-C level has not been 
determined [1, 17, 18].
5.1. Methods of determination
The Abbel-Kendall method, a  modification 
of the Liebermann-Burchard chemical method, 
based on cholesterol reaction with sulphuric acid, 
is the reference method for cholesterol determi-
nation [19, 20]. In medical diagnostic laboratory 
practice, the serum/plasma TC level is determined 
employing enzymatic methods and using auto-
mated analysers. In a typical method, after enzy-
matic hydrolysis of cholesterol esters by cholester-
ol esterase, cholesterol is oxidized by cholesterol 
oxidase to Δ4-cholestenone, with the formation of 
hydrogen peroxide (H2O2) reactive with 4-amino-
phenazone and 4-chlorophenol with the involve-
ment of peroxidase, forming a red product (Trinder 
reaction), the concentration of which is deter-
mined by spectrophotometry [15, 21].
The total allowable error for TC determination, 
recommended by NCEP, is ±9% while the one used 
by COBJwDL – ±8%.
5.2. Reporting of results
Alongside the TC level, a laboratory report should 
include information on the desirable (target) values 
with regard to cardiovascular risk (Table II).
6. HDL CHoLeSTeroL
High density lipoproteins (HDL), unlike oth-
er lipoproteins, are characterized by a  low lipid 
and a high protein content. HDL transport about 
25% of the cholesterol present in the blood, and 
its content in the particles of these lipoproteins 
is considerably variable. Therefore, plasma HDL-C 
level provides indirect and inaccurate information 
on HDL content in the blood. Nonetheless, HDL-C 
measurement remains a basic test for the assess-
ment of HDL content in the blood as methods of 
direct measurement of the number of HDL par-
ticles (HDL-P), and their individual subfractions 
Table II. Desirable TC plasma/serum levels [6, 8]
Desirable levels fasting and non-fasting
TC level [mg/dl] TC level [mmol/l]
< 190 < 5.0
Unit conversion: [mg/dl] × 0.026 = [mmol/l].
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(measured with e.g. nuclear magnetic resonance 
spectrometry, ion mobility spectrometry, electro-
phoretic techniques) are not available in routine 
laboratory diagnostics and do not provide suffi-
cient new data to be recommend. From a practi-
cal point of view, the EAS/ESC guidelines do not 
recommend HDL-C assessment as a  treatment 
goal or for predicting CV risk and monitoring lip-
id disorders treatment; HDL-C may, however, be 
considered as an additional parameter for the risk 
stratification in the SCORE risk scale.
6.1. Methods of determination
The HDL-C level is measured in the serum or 
plasma. Previous methods required ultracentrifu-
gation or more frequently precipitation in order to 
isolate the HDL fractions. The reference method 
for HDL-C determination combines ultracentrifu-
gation and chemical precipitation to separate HDL 
from other lipoprotein classes containing apoB 
[22]. In the late 1990s, direct (homogeneous) as-
says for HDL-C determination were introduced 
into medical diagnostic laboratories, replacing 
precipitation methods [3]. Direct assay, without 
precipitation of LDL and VLDL, is possible thanks 
to the use of a detergent which dissolves HDL and 
adsorptively blocks access to cholesterol in VLDL 
and LDL particles to enzymes (cholesterol ester-
ase and oxidase). New generation homogeneous 
methods (several types) are widely available, and 
ready-to-use reagents enable full automation of 
HDL-C measurement in the primary serum/plasma 
sample [3]. Direct methods are well standardized 
(for samples collected from healthy individuals) 
and ensure sufficient accuracy of measurement. 
Measurement bias, if occurs, is usually related 
to the matrix effect, e.g. in dyslipidemia. In mea-
suring the HDL-C level, neither precipitation nor 
current direct methods differentiate between the 
HDL subclasses discussed below. 
According to the NCEP recommendations, the 
total allowable error for HDL-C direct method mea-
surement is ±13% for normolipidemic samples 
and between –20% to +36% for dyslipidemic sam-
ples. The majority of inaccurate results are seen 
at HDL-C levels < 40 mg/dl (< 0.8 mmol/l) [22]. In 
COBJwDL surveys, the allowable error is ±15%.
HDL comprise a  heterogeneous group of small 
discoid and spherical particles differing in density 
(1.063–1.21 g/ml), size (7.6–10.6 nm) and electro-
phoretic mobility as well as the content of apolipopro-
teins and lipids [23, 24]. Apolipoprotein A-I (apoA-I) 
is the major protein component of the HDL particle, 
accounting for about 70% of the protein content and 
playing a  significant role in HDL function and bio-
genesis [25]. HDL may be fractionated using differ-
ent techniques, depending on their physicochemical 
properties and composition [26] (Figure 3).
Two fractions are obtained by sequential ultra-
centrifugation: HDL2 – a fraction of large light par-
figure 3. HDL subpopulations and measurement techniques
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ticles, high in lipids, with a density of 1.063–1.125 
g/ml, and HDL3 – a  fraction of small, dense, pro-
tein-rich particles, with a density of 1.125–1.21 g/ml. 
HDL2 and HDL3 are not uniform fractions. Using 
gradient polyacrylamide gel electrophoresis, they 
can be separated into five subfractions of decreas-
ing size: HDL2b, HDL2a, HDL3a, HDL3b and HDL3c. 
Using bidirectional electrophoresis, which enables 
separation according to particle charge and size, 
more than 10 HDL subfractions were obtained. To 
standardize the nomenclature, HDL division into 
five subclasses according to their physical and 
chemical properties has been proposed recently 
[27]: 1) very large HDL, 2) large HDL, 3) medium 
HDL, 4) small HDL and 5) very small HDL.
The analytical methods/measurement tech-
niques listed in Figure 3 enable direct determina-
tion of HDL particles in plasma/serum (HDL-P) as 
well as differentiation of their subfractions, which 
allows a certain functional characteristic [26, 28]. 
Due to differences in the results for individual HDL 
subfractions with regard to their predictive prop-
erties (more studies indicate that small dense HDL 
are a proatherogenic fraction), they are assessed 
mainly for research purposes [29–31].
recommendations
At present, HDL-P measurement requires stan-
dardization of methods and determination of 
the desirable (target) levels, which makes rou-
tine testing unavailable.
Currently, there is no direct evidence of the 
usefulness of HDL subfractions determination 
in cardiovascular risk assessment.
6.2. Reporting of results
Alongside the HDL-C level, a  laboratory report 
should include information on the desirable (tar-
get) values with regard to cardiovascular risk (Ta-
ble III).
7. DySfunCTIonAL HDL
The anti-atherosclerotic effect of HDL is relat-
ed primarily to its involvement in reverse cho-
lesterol transport as well as anti-inflammatory, 
antioxidant, antiapoptotic, anticoagulant, cyto-
protective and vasodilator activity. Altered HDL 
properties, in particular the development of dys-
functional HDL particles, constitute a  factor for 
an increased cardiovascular risk [32–35]. The for-
mation of dysfunctional HDL is caused primarily 
by inflammation, as well as oxidative stress and 
glycation. Increased expression of myeloperox-
idases (MPO, E.C. 1.11.1.7) plays an important 
role here [36]. MPO catalyses apoA-I  modifica-
tions and, as a result, inhibits ABCA1-dependent 
reverse cholesterol transport, contributing to the 
formation of foam cells and the development of 
fatty infiltration of a  blood vessel (Figure 4 A). 
Table III. Desirable and alarming HDL-C plasma/
serum levels [6, 8]
Gender Desirable levels fasting and non-fasting
HDL-C level  
[mg/dl]
HDL-C level 
[mmol/l]
Females > 45 > 1.2
Males > 40 > 1.0
Unit conversion: [mg/dl] × 0.026 = [mmol/l].
figure 4. Dysfunctional HDL particles: A – HDL modified by myeloperoxidase, b – inflammatory HDL
SAA – serum amyloid A, PON-1 – paraoxonase-1, GPx – glutathione peroxidase, RCT – reverse cholesterol transport,  
ABCA1 – ATP-binding membrane cassette transporter A1.
MPO
↓ ABCA1
Apo A-I
A b
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Inflammation also induces HDL transformation 
consisting in the: 
•	 Deficiency/absence of paraoxonase (PON-1) 
and glutathione peroxidase (GPX), which inhib-
it LDL oxidation,
•	 Change in the apoA-I/apoA-II ratio,
•	 Presence of acute phase proteins: serum am-
yloid A (SAA) and ceruloplasmin (Figure 4 B).
PON-1 (aryldialkylphosphatase, E.C. 3.1.8.1) 
plays a  special role in reducing CV risk. It is an 
enzyme responsible for the hydrolysis of toxic or-
ganophosphorus compounds, phospholipid perox-
ides and cholesterol ester hydroxides [37]. The role 
of PON-1 is to protect the LDL fraction from ox-
idative modification, preventing the formation of 
atherogenic oxidized LDL particles (oxLDL) [38, 39].
HDL-C level does not provide information on 
HDL functionality. To date, no methods for routine 
direct determination of dysfunctional HDL have 
been developed. Knowing the mechanisms un-
derlying their formation, one might attempt pre-
diction of this process in inflammation diagnosed 
and monitored using standard markers (C-reac-
tive protein (CRP), interleukin-6 (IL-6)) as well as 
MPO and PON-1 directly related to dysfunction-
ality of these lipoproteins. From a practical point 
of view, in the absence of a gold standard for (re-
producible, simple and cheap) assessment of HDL 
functionality, determination of dysfunctional HDL 
has no clinical significance. Nonetheless, knowl-
edge of this topic is crucial since even in primary 
prevention in obese patients and smokers or in 
secondary prevention and/or chronic kidney dis-
ease, most HDL particles might be dysfunctional 
and might have atherogenic properties similar to 
those of LDL particles. 
recommendations
Clinical utility of determination of dysfunction-
al HDL and biomarkers such as MPO and PON-1 
in cardiovascular risk assessment has not been 
established and requires further studies. So far, 
it has no clinical significance. 
8. LDL CHoLeSTeroL 
Low-density lipoproteins (LDL) transport about 
70% of the cholesterol present in the blood. Cho-
lesterol and its esters account for 40–50% of the 
LDL particle mass. Due to the key predictive role 
of LDL in atherogenesis, the LDL-C level, which in-
directly reflects the LDL content in the blood, is 
a primary lipid factor of cardiovascular risk, and 
its specific values constitute a goal for lipid-low-
ering therapy. As blood samples for lipid profile 
do not need to be collected in a fasting state, the 
testing is more available and the calculation/de-
termination of the LDL-C level is easier [2, 3, 6, 8].
8.1. Methods of determination/calculation
Beta quantification based on preparative ul-
tracentrifugation of the material (serum, plasma), 
separating lipoproteins into two fractions accord-
ing to their density: CM and VLDL (rejected), and 
LDL, HDL, IDL and Lp(a), is the reference method 
for determining the LDL-C level. The LDL-C and 
Lp(a) cholesterol levels are determined in this frac-
tion. In everyday practice, the LDL-C level is usual-
ly calculated, less frequently determined by direct 
(homogeneous) methods.
The Friedewald formula, using determined 
TC, HDL-C and TG levels and the adopted TG-to-
VLDL-C ratio, is widely used to calculate the L DL-C 
level [40]: LDL-C = TC – HDL-C – TG/5 (mg/dl) or 
LDL-C = TC – HDL-C – TG/2.2 (mmol/l).
This formula should not be used if the TG level 
is high (> 4.5 mmol/l, 400 mg/dl) – the TG-VLDL-C 
ratio is different than the one adopted in the for-
mula. Calculation of the LDL-C level using the Frie-
dewald formula may also be confounded by the 
presence of IDL and in states associated with al-
tered composition of lipoprotein particles (obesity, 
type 2 diabetes, metabolic syndrome, kidney dis-
eases, liver diseases). The Friedewald formula, even 
if the pre-analytical requirements are met, tends to 
underestimate the LDL-C levels at low LDL-C levels 
(< 1.8 mmol/l, 70 mg/dl) and TG levels (> 1.7 
mmol/l, 150 mg/dl) [41]. In addition, the LDL-C 
calculated is confounded by the sum of errors in 
determination, the results of which are used in the 
formula.
The Martin-Hopkins equation is one of several 
(most recent) modifications of the Friedewald for-
mula proposed (2013) [40]: LDL-C = TC – HDL-C – 
TG/x (mg/dl), where x – TG-to-VLDL-C ratio based 
on TG and non-HDL-C levels; values are available 
in special tables or online calculators, available 
e.g. www.ldlcalculator.com. The formula has been 
shown to be more accurate than the Friedewald 
formula in determining the LDL-C level if it is low 
and if the TG level amounts to 2.0–4.5 mmol/l 
(175–400 mg/dl) [41–43].
The LDL-C level can be determined using direct 
(homogeneous) methods. The current third-gen-
eration methods involve the use of reagents con-
taining different detergents, surfactants, carbo-
hydrate derivatives and other factors that block 
or dissolve individual lipoprotein fractions, which 
selectively make LDL-C available for cholesterol 
oxidase and esterase. These methods allow the 
use of automated analysers. Due to consider-
able methodological variability, direct methods 
of LDL-C determination differ in accuracy (trace-
ability to the reference method) and precision of 
assays [43]. The total allowable error for the de-
termination/calculation of the LDL-C level recom-
mended by NCEP is ±12%.
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recommendations
The LDL-C level can be calculated using the 
Friedewald or Martin-Hopkins formula at TG 
≤ 4.5 mmol/l (400 mg/dl); calculations us-
ing the Martin-Hopkins equation are more 
accurate at low LDL-C levels and the TG level 
> 2.0 mmol/l (175 mg/dl) and should be rec-
ommended. 
In individuals with the TG level > 4.5 mmol/l 
(400 mg/dl), obesity, diabetes mellitus, meta-
bolic syndrome and low TC and LDL-C level, cal-
culation of non-HDL-C or apoB measurement 
rather than LDL-C is recommended.
8.2. Reporting of results
Alongside the calculated/determined LDL-C 
level, a  laboratory report should include informa-
tion on the formula used or the use of a  direct 
determination method as well as the desirable 
(target) values with regard to cardiovascular risk 
(Table IV) and alarming values indicating severe 
dyslipidemia (Table V).
9. non-HDL CHoLeSTeroL 
Non-HDL cholesterol (non-HDL-C) is an inte-
grated indicator of the level of all lipoproteins, 
which are known to be associated with the initia-
tion and progression of atherosclerosis. These are 
apoB-containing particles: LDL, VLDL, IDL, CM, CM 
Table IV. Updated cardiovascular risk categories based on the 2019 ESC/EAS guidelines. The level of risk is defined 
by the presence of at least one of the factors listed in individual categories
extreme Status post-acute coronary syndrome (ACS) and a history of another vascular event in last 2 years; 
status post-ACS and the presence of peripheral artery disease or polyvascular vascular disease1; 
status post-ACS and coexistent multivessel coronary artery disease or status post-ACS and familial 
hypercholesterolaemia (FH) – despite optimal treatment with maximum tolerated statin doses2
Very high Cardiovascular disease documented clinically or by imaging examinations; diabetes mellitus with 
organ damage3 or at least 3 risk factors4, early-onset type 1 diabetes lasting for > 20 years; chronic 
kidney disease with eGFR < 30 ml/min/1.73 m2; FH with CVD or another major risk factor4; risk ≥ 10% 
in Pol-SCORE
High Significantly intense single risk factor, especially TC > 8 mmol/l (> 310 mg/dl), LDL-C > 5.0 mmol/l  
(> 190 mg/dl) or blood pressure ≥ 180/110 mm Hg; FH without other risk factors; diabetes lasting for 
≥ 10 years without organ damage or another additional risk factor4; chronic kidney disease with  
eGFR 30–59 ml/min/1.73 m2; risk of ≥ 5% and < 10% in Pol-SCORE
Moderate Type 1 diabetes in patients < 35 years of age; type 2 diabetes in patients < 50 years of age lasting  
< 10 years, with no other risk factors; risk of < 5% as per Pol-SCORE
Low Risk of < 1% as per Pol-SCORE
1Polivascular artery disease (= multilevel atherosclerosis) is defined as the occurrence of significant atherosclerotic lesions in at least 
two of the three vascular beds – coronary vessels, carotid and vertebral arteries and/or peripheral vessels. 2Applies to all four clinical 
situations related to an extreme risk. 3Organ damage is defined as the presence of increased albuminuria, retinopathy or neuropathy. 4Age, 
hypertension, dyslipidaemia, smoking, obesity.
Table V. Desirable and alarming LDL-C plasma/serum levels [6, 8]
Cardiovascular risk Desirable levels fasting and non-fasting
LDL-C level [mg/dl] LDL-C level [mmol/l]
Extreme < 40 < 1.0
Very high Reduction by ≥ 50% and < 55 Reduction by ≥ 50% and < 1.4
High Reduction by ≥ 50% and < 70 Reduction by ≥ 50% and < 1.8
Moderate < 100 < 2.6
Low < 115 < 3.0
Alarming levels
Homozygous familial hypercholesterolaemia with 
an extremely high cardiovascular risk:
In untreated individuals > 500 > 13.0
In treated individuals > 300 > 8.0
Heterozygous familial hypercholesterolaemia with 
a high cardiovascular risk in untreated individuals*
> 190 > 5.0
*In treated individuals, the LDL-C level multiplied by 1.43 defines the LDL-C level that would be seen without treatment; Unit conversion: 
[mg/dl] × 0.026 = [mmol/l].
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remnants, VLDL remnants and Lp(a). Non-HDL-C 
determination is very important for CV risk as-
sessment. It should be a  permanent element of 
the lipid profile as it represents the concentration 
of all atherogenic lipoprotein fractions. The avail-
able studies show that it is more predictive in CV 
risk assessment than LDL-C [44, 45].
The non-HDL-C level is calculated using the fol-
lowing formula: non-HDL-C = TC – HDL-C. 
Non-HDL-C calculation is more reliable than 
the calculation of LDL-C [45, 46]. As with other 
formulas, the accuracy of non-HDL-C calculation 
depends on the biological and analytical variabili-
ty of the TC and HDL-C levels. However, the biolog-
ical variability of HDL-C is much lower than that of 
other lipid parameters, especially TG. In addition, 
HDL-C levels are much lower than the TC levels, 
which minimises their effect on changes in the 
calculated non-HDL-C level.
9.1. Reporting of results
Alongside the calculated non-HDL-C level, 
a laboratory report should include information on 
the desirable (target) values with regard to cardio-
vascular risk (Table VI).
recommendations
Non-HDL-C is an indicator of cardiovascular 
risk recommended especially in individuals 
with the TG level > 4.5 mmol/l (400 mg/dl), 
obesity, diabetes mellitus, metabolic syndrome 
and low TC and/ LDL-C level. 
The calculated non-HDL-C level should be rou-
tinely provided in every lipid profile laboratory 
report.
10. APoLIPoProTeIn b 
Apolipoprotein B (apoB), which is a  structur-
al component of all lipoproteins except for HDL, 
Table VI. Desirable non-HDL-C plasma/serum levels 
[6, 8]
Cardiovascular risk Desirable levels fasting and 
non-fasting*
non-HDL-C 
level [mg/dl]
non-HDL-C 
level [mmol/l]
Extreme < 70 < 1.8
Very high < 85 < 2.2
High < 100 < 2.6
Moderate < 130 < 3.4
*According to EAS/EFLM (2016), the difference in the cut-off 
value for moderate cardiovascular risk in the fasting and non-
fasting state is minimal, i.e. 3.8 mmol/l (145 mg/dl) vs. 3.9 mmol/l 
(150 mg/dl) [6], and therefore may be omitted; Unit conversion: 
[mg/dl] × 0.026 = [mmol/l].
occurs as two isoforms: apoB 100 (MM 550 kD), 
synthesized in hepatocytes, present in VLDL, IDL 
and LDL, and its fragment, apoB 48 (MM 265 kD), 
synthesized in enterocytes, present in CM and 
their remnants [6, 47].
10.1. Methods of determination
Serum/plasma apoB is determined by immuno-
turbidimetry and immunonephelometry. The anti-
bodies used in these methods are directed against 
apoB 100 while some of the methods involve also 
determination of apoB 48. In fasting blood sam-
ples apoB 100 accounts for > 90% of apoB. Due to 
a very short half-life of VLDL, it is assumed that at 
the TG level < 2.3 mmol/l (200 mg/dl) almost all 
apoB molecules determined are the LDL compo-
nents. Since one apoB 100 molecule is found in 
every LDL particle, the apoB level determined is 
a measure of the serum/plasma LDL level.
Immunochemical apoB assays are standardised 
using secondary IFCC/WHO SP3-08 reference ma-
terial as well as primary reference material – LDL 
fraction obtained by ultracentrifugation. The total 
allowable error for determination of the apoB level 
recommended by NCEP is ±6%.
10.2. Reporting of results
Alongside the apoB level, a  laboratory report 
should include information on the desirable (tar-
get) values with regard to cardiovascular risk (Ta-
ble VII).
recommendations
Determination of the apoB level may be an 
alternative to LDL-C measurement, if avail-
able, especially in individuals with the TG level 
> 4.5 mmol/l (400 mg/dl), obesity, diabetes 
mellitus, metabolic syndrome and low TC and/ 
LDL-C level. 
Calculated ratios (indices) of lipid profile re-
sults such as TC/HDL-C, LDL-C/HDL-C and 
apoB/apoA-I  are not clinically significant for 
cardiovascular risk assessment.
Table VII. Desirable apoB plasma/serum levels [6, 8]
Cardiovascular risk Desirable levels fasting and 
non-fasting
apob level 
[mg/dl]
apob level 
[g/l]
Extreme < 55 < 0.55
Very high < 65 < 0.65
High < 80 < 0.8
Moderate < 100 < 1.0
Unit conversion: [mg/dl] × 0.01 = [g/l].
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11. LIPoProTeIn (A)
Lipoprotein (a) (Lp[a]) particles are a  subpop-
ulation of LDL of a  similar structure, containing 
one apolipoprotein B 100 molecule with which 
apolipoprotein (a) [apo(a)] is bound covalently 
by a  disulphide bridge. The apo(a) molecule is 
characterized by marked amino acid sequence 
homology with plasminogen; it contains the pro-
tease domain and the so-called Kringle IV and 
V domains. The molecular mass of Lp(a) shows 
high interindividual variability, dependent on the 
number of repeats of the Kringle IV type 2 (KIV-2) 
domain, which may range from 3 to 40 and is 
genetically determined by the number of tandem 
repeats of the genome sequence in the LPA gene. 
This genetically determined size of the Lp(a) par-
ticle is inversely proportional to the rate of its syn-
thesis mainly in the liver and the serum/plasma 
concentration – particles of a lower mass (lower 
number of KIV-2 repeats) are present in a  high-
er concentration while particles of a higher mass 
(high number of KIV-2 repeats) – in a lower con-
centration [6, 48]. 
In Poland, lipoprotein(a) levels are still very 
rarely determined and the knowledge on this sub-
ject is very limited. Therefore, every effort should 
be made to change it as soon as possible. This is 
related to enormous advances in this field of sci-
ence. Today, we know that it is an independent 
risk factor for cardiovascular diseases and that up 
to 20–30% of patients with familial hypercholes-
terolaemia and/or acute coronary syndrome may 
have an elevated Lp(a) level of over 50 mg/dl, 
with frequently targeted LDL-C levels, and that 
the Lp(a) level may be reduced pharmacologically 
[49–51].
11.1. Methods of determination
The Lp(a) level is determined in plasma/se-
rum using mainly immunoassays, e.g. immuno-
turbidimetry, immunonephelometry and various 
immunoenzymatic methods, including ELISA. 
The standardisation of immunochemical meth-
ods for Lp(a) determination is based on trace-
ability of calibrators to the original IFCC/WHO 
reference material. The results obtained using 
different methods are still insufficiently har-
monised, which is thought to result from the 
effect of the apo(a) molecule size variability on 
Lp(a) immunoassays, which may lead to over-
estimation in the case of large isoforms and 
underestimation in the case of small isoforms 
[52–55].
11.2. Reporting of results
Alongside the Lp(a) level, a  laboratory report 
should include information on the desirable (tar-
get) values with regard to cardiovascular risk as 
well as alarming values indicating severe dyslipid-
emia (Table VIII).
LDL cholesterol is measured or calculated joint-
ly with the Lp(a) cholesterol. Lp(a), especially at 
high concentrations, may result in overestima-
tion of the LDL-C level. The LDL-C level calculated 
using the Friedewald formula can be adjusted to 
the Lp(a) level using Dahlen’s modification of the 
formula, based on the assumption that choles-
terol accounts for 30% of the Lp(a) particle mass 
[6, 55]: LDL-Cadj = TC – HDL-C – TG/5 – [Lp(a) × 0.3] 
(all concentrations in mg/dl).
The same adjustment may be made if the 
LDL-C level is calculated using other formulas or is 
determined using direct methods.
recommendations
It should be an aim that every adult has his/her 
Lp(a) level determined at least once in a  life-
time so that the highest risk patients with the 
Lp(a) level > 180 mg/dl are identified.
Even the Lp(a) level of > 30 mg/dl significant-
ly increases the risk of cardiovascular events. 
Therefore, Lp(a) measurement should be con-
sidered in all patients with premature cardio-
vascular disease, non-responders to statin 
therapy and individuals with a border interme-
diate/high risk, to ensure better risk stratifi-
cation.
In the case of patients with the Lp(a) level de-
termined as part of an extended lipid profile, 
the LDL-C level should be adjusted using the 
Dahlen’s modification.
12. CM AnD VLDL reMnAnT  
CHoLeSTeroL
TG-rich CM and VLDL remnant cholesterol, 
formed from these lipoproteins under the influ-
Table VIII. Desirable and alarming Lp(a) plasma/
serum levels [6, 8, 54]
Variable Lp(a) level
[mg/dl]
Lp(a) level
[nmol/l]
Desirable levels fasting and 
non-fasting
< 30 < 75
Alarming levels
Moderate risk 30–50 75–125
High risk > 50 > 125
Very high risk of myocardial 
infarction and aortic valve 
stenosis
> 180 > 450
Unit conversion: [mg/dl] × 2.5 = [nmol/l]* – *due to heterogeneity 
of the Lp(a) MM unit conversion gives an approximate result.
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ence of endothelial and hepatic lipoprotein lipase 
and CETP, have an LDL-independent atherogen-
ic effect. Particles of remnants, which are much 
smaller than their precursors, enter the internal 
membrane of arteries, are absorbed by macro-
phages and induce foam cell formation; during 
their formation, reactive oxygen species are re-
leased, damaging the endothelium and initiating 
inflammation [6, 56]. Although scientific evidence 
clearly indicates that assessment of the remnants 
levels may help to reduce residual cardiovascular 
risk [57], determination of remnants still plays 
a minor role in everyday clinical practice. However, 
determination of their blood levels may be consid-
ered a part of overall assessment of the patient’s 
cardiovascular risk.
12.1. Methods of determination
CM remnants and VLDL remnants are mea-
sured in non-fasting plasma or serum samples. 
Immunochemical methods for determination of 
complete particles of remnants have not found 
their use in practice. Recently, a  homogeneous 
method for determination of the levels of CM and 
VLDL remnant cholesterol (Remn-C) has been de-
veloped, which allows the use of automated anal-
ysers. The Remn-C level can easily be calculated 
using the following formula: Remn-C = TC – HDL-C 
– LDL-C.
The LDL-C level used in the formula must be de-
termined using a direct method, in a non-fasting 
sample. The Remn-C level calculated shows a high 
consistency with the level determined using a di-
rect method [6].
12.2. Reporting of results
Alongside the calculated Remn-C level, a lab-
oratory report should include information on the 
desirable (target) values with regard to cardio-
vascular risk. In the Community General Popula-
tion Study, median (interquartile range) Remn-C 
level in the study population was 0.6 (0.4–0.9) 
mmol/l (23 [15–35] mg/dl) [58]. According to 
various clinical and epidemiological studies, the 
desirable Remn-C level should be < 0.9 mmol/l 
(< 35 mg/dl) [6].
recommendations
If the LDL-C level in the lipid profile was de-
termined in a non-fasting state using a direct 
method, the Remn-C level may be additionally 
calculated. However, as the LDL-C measure-
ment is required and no recommended target 
Remn-C levels are available, its use in clinical 
practice is still limited.
13. LIPID ProfILe – LAborATory rePorT
Lipid profile includes a battery of blood serum 
or plasma tests and calculations aimed at iden-
tification of dyslipidemia as a cardiovascular risk 
factor as well as treatment monitoring: total cho-
lesterol (TC) level, HDL cholesterol (HDL-C) level, 
LDL cholesterol (LDL-C) level, non-HDL cholesterol 
(non-HDL-C) level, triglycerides (TG) level.
Lipid profile may be supplemented with the 
following parameters, determined as per indica-
tions: apolipoprotein B (apoB) level, lipoprotein (a) 
[Lp(a)] level, CM and VLDL remnants cholesterol 
(Remn-C).
The following have an experimental (mainly re-
search) use: myeloperoxidase (MPO) level/activity, 
paraoxonase (PON-1) level/activity.
In addition to the results of measurements and 
calculations, a  lipid profile laboratory report (Ta- 
ble IX) should include information on how the 
LDL-C level was defined (determined) as well as 
targeted (desirable) concentrations of the analytes 
determined. If severe dyslipidemia is suspected, 
it should also include information on the need to 
seek urgent medical attention if the LDL-C level 
indicates a  possible diagnosis of heterozygous 
(> 190 mg/dl/> 5.0 mmol/l) or homozygous 
(> 500 mg/dl/> 13.0 mmol/l) familial hypercho-
lesterolaemia (FH), if the Lp(a) level >180 mg/dl 
(450 nmol/l) indicates a very high risk of acute CV 
events, or the TG level > 880 mg/l (10.0 mmol/l) 
indicates a  high risk of acute pancreatitis and 
in case of some typical symptoms (early onset 
of symptoms, unexplained recurrent abdominal 
pain, history of pancreatitis), the possible risk 
of familial chylomicronemia syndrome (FCS). In-
formation provided on a  lipid profile order form 
on whether a  patient is overweight/obese and/
or suffers from diabetes and whether he/she is 
receiving a  lipid-lowering therapy is helpful in 
laboratory interpretation and authorisation of 
obtained results.
recommendations
The need for urgent medical consultation 
should be noted on a lipid profile laboratory 
report, if alarming levels indicating severe dys-
lipidemia have been found. 
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